Skip to main content

FDA Approves Lynparza for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

TUESDAY, June 6, 2023 -- The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, metastatic, castration-resistant prostate cancer (mCRPC).

The approval was based on findings from the PROpel trial in which 796 patients with mCRPC were randomly assigned (1:1) to receive either Lynparza with abiraterone or placebo with abiraterone and also received prednisone or prednisolone. According to the results of the study, there was a statistically significant improvement in investigator-assessed radiological progression-free survival for Lynparza with abiraterone versus placebo with abiraterone. A subgroup analysis suggested that improvement in radiological progression-free survival was driven by patients with BRCA-mutated cancer. Lynparza was approved with a companion diagnostic test to assess BRCA mutational status.

For patients taking Lynparza, the most common adverse reactions included anemia (48 percent), fatigue (38 percent), nausea (30 percent), diarrhea (19 percent), decreased appetite (16 percent), lymphopenia (14 percent), dizziness (14 percent), and abdominal pain (13 percent). Nearly one in five patients (18 percent) required at least one blood transfusion.

Approval of Lynparza was granted to AstraZeneca.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted June 2023

Read this next

Study Confirms Effectiveness of 'Watch-and-Wait' Approach to Prostate Cancer

THURSDAY, May 30, 2024 -- For a large percentage of men with prostate cancer, the tumor may be so slow-growing that doctors advise a "watch-and-wait" approach instead of active...

Report Highlights Big Gaps in Cancer Outcomes Based on Race

WEDNESDAY, May 15, 2024 -- U.S. cancer death rates are continuing to drop, falling by 33% between 1991 and 2020. However, not all Americans are reaping the benefits from advances...

Urine Test Might Help Men Skip Prostate Biopsies

THURSDAY, April 18, 2024 -- When prostate cancer strikes, one question is paramount: Is it aggressive and requiring immediate treatment, or slow-growing and worthy of monitoring...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.